- Home
- TCBIO vs TNGX Comparison
TCBIO vs TNGX Comparison
Compare TCBIO & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
TCBIO
Texas Capital Bancshares Inc. Depositary Shares 5.75% Fixed Rate Non-Cumulative Perpetual Preferred Stock Series B
Current Price
Company Overview
Basic Information| Metric | TCBIO | TNGX |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | United States |
| Employees | 1818 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 1.4B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | TCBIO | TNGX |
|---|---|---|
| Price | $20.65 | $9.31 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $12.50 |
| AVG Volume (30 Days) | N/A | ★ 2.6M |
| Earning Date | N/A | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $66,501,000.00 |
| Revenue This Year | N/A | $53.01 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 53.29 |
| 52 Week Low | N/A | $1.03 |
| 52 Week High | N/A | $11.20 |
Technical Indicators
Market Signals| Indicator | TCBIO | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 41.28 | 51.72 |
| Support Level | $20.42 | $8.89 |
| Resistance Level | $20.97 | $10.22 |
| Average True Range (ATR) | 0.26 | 0.63 |
| MACD | -0.05 | -0.14 |
| Stochastic Oscillator | 16.67 | 18.53 |
Price Performance
Historical ComparisonAbout TCBIO Texas Capital Bancshares Inc. Depositary Shares 5.75% Fixed Rate Non-Cumulative Perpetual Preferred Stock Series B
Texas Capital Bancshares Inc is a registered bank holding company and a full-service financial services firm that delivers customised solutions to businesses, entrepreneurs and individual customers. It is a secured lender with the majority of the loans held for investment, excluding mortgage finance loans and other national lines of business. Texas Capital has established commercial banking, consumer banking, investment banking and wealth management capabilities.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.